Maxim Group Maintains a Buy Rating on Mesoblast Ltd (MESO)


Maxim Group analyst Jason McCarthy maintained a Buy rating on Mesoblast Ltd (MESO) today and set a price target of $16. The company’s shares opened today at $4.80, close to its 52-week low of $4.58.

McCarthy said:

“Mesoblast announced the first meeting of the with partner Tasly Pharmaceutical (SHA: 600535 – NR) to discuss the Chinese regulatory pathway for MPC-150-IM in heart failure (HF). The companies plan to meet with Chinese regulators (NMPA) in 1Q19 to determine the path forward, including leveraging existing HF safety and efficacy data already obtained by Mesoblast.”

According to TipRanks.com, McCarthy is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -2.4% and a 32.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.

Mesoblast Ltd has an analyst consensus of Strong Buy, with a price target consensus of $17.75, which is a 269.8% upside from current levels. In a report issued on November 11, Cantor Fitzgerald also maintained a Buy rating on the stock with a $23 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $8.78 and a one-year low of $4.58. Currently, Mesoblast Ltd has an average volume of 81.97K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts